Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Benazepril plus hydrochlorothiazide · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Benazepril plus hydrochlorothiazide | DRUG | - |
Inclusion Criteria: * Male or female patients, age 18 or older * Given informed consent * Diagnosed as having mild to moderate essential hypertension Exclusion Criteria: * Severe hypertension * Significant preexisting cardiovascular and cerebrovascular disease * Diabetes mellitus type 1 or poorly...
Benazepril plus hydrochlorothiazide is used for the treatment of hypertension, also known as high blood pressure. It is a combination of two small molecule drugs being developed by Novartis AG for this cardiovascular condition. The drug is intended for patients with mild to moderate essential hypertension.
Benazepril plus hydrochlorothiazide is a combination of two active ingredients: benazepril, an ACE inhibitor, and hydrochlorothiazide, a thiazide diuretic. Together, they work to lower blood pressure by relaxing blood vessels and reducing fluid volume, respectively, in patients with hypertension.
Benazepril plus hydrochlorothiazide is being developed by Novartis AG, a multinational pharmaceutical company. Novartis is listed on the stock exchange under the ticker symbol NVS. The company is conducting clinical trials to evaluate this combination therapy for the treatment of hypertension.
Benazepril plus hydrochlorothiazide is in Phase 3 clinical development. It is an investigational drug and has not yet been approved by regulatory authorities. The Phase 3 trial has been completed, and the drug is being studied for its efficacy and safety in patients with hypertension.
Benazepril plus hydrochlorothiazide has been studied in one Phase 3 clinical trial with the identifier NCT00367094. This trial, titled 'Combination of Benazepril Plus Hydrochlorothiazide in Chinese Patients With Mild to Moderate Essential Hypertension,' was a randomized, double-blind study that enrolled 296 participants in China. The trial has been completed.
Benazepril plus hydrochlorothiazide is a combination of benazepril and hydrochlorothiazide, which is also marketed under the brand name Lotensin HCT. The drug combines an ACE inhibitor with a diuretic to manage hypertension. Novartis AG is the developer of this combination therapy.